Mark Scalzo

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

D. Murphy, T. Akhurst, R. Hicks, 2018, The Lancet. Oncology.

Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors

R. Hicks, M. Hofman, J. Violet, 2019, The Journal of Nuclear Medicine.

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

D. Murphy, T. Akhurst, B. Tran, 2019, The Journal of Nuclear Medicine.

Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ( 177 Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer

D. Murphy, T. Akhurst, B. Tran, 2019 .

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

N. Lawrentschuk, D. Murphy, S. Keam, 2020, European urology focus.